期刊文献+

肿瘤生物化疗的研究进展 被引量:2

Research progress on tumor biochemotherapy
原文传递
导出
摘要 近年来随着科学技术的发展,恶性肿瘤的早期诊断率有所提高,但其治疗仍是一个难题。传统的手术、化疗、放疗并不能从根本上消灭肿瘤,大部分肿瘤患者的长期生存率较低。在生物和免疫学技术飞速发展的推动下,生物治疗的出现为人们对抗肿瘤带来了新的希望。生物治疗与化疗的结合——生物化疗更是为恶性肿瘤的治疗带来了新的理念,并且得到了较好的发展。 With the development of science and technology in recent years, the rate of early diagnosis of malignant tumors has increased, but the treatment is still a difficult problem. Traditional surgery, chemotherapy, radiotherapy can not fundamentally eradicate tumor, and the long-term survival rate of most patients is very low. With the rapid development of biological and immunological techniques, the emergence of biotherapy has brought new hope against tumor. Biochemotherapy, the combination of biotherapy and chemotherapy, has brought new ideas for the treatment of malignant tumors, and it has been rapidly developed in recent years.
出处 《国际呼吸杂志》 2010年第18期1137-1141,共5页 International Journal of Respiration
关键词 化疗 生物治疗 生物化疗 恶性肿瘤 Chemotherapy Biotherapy Biochemotherapy Malignant tumor
  • 相关文献

参考文献39

  • 1Zitvogel L,Apetoh L,Ghiringhelli F,et al.The anticancer immune response:indispensable for therapeutic success?.J Clin Invest,2008,118:1991-2001. 被引量:1
  • 2罗荣城,姚广裕.肿瘤分子靶向治疗与生物化疗进展[J].中国肿瘤生物治疗杂志,2009,16(2):101-105. 被引量:23
  • 3Kempf RA,Mitchell MS.Effects of chemotherapeutic agents on the immune response.Ⅰ.Cancer Invest,1984,2:459-466. 被引量:1
  • 4Ménard C,Martin F,Apetoh L,et al.Cancer chemotherapy:not only a direct cytotoxic effect,but also an adjuvant for antitumor immunity.Cancer Immunol Immunother,2008,57:1579-1587. 被引量:1
  • 5Cunningham D,Humblet Y,Siena S,et al.Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer.N Engl J Med,2004,351;337-345. 被引量:1
  • 6Sinkovics JG,Horvath JC.Evidence accumulating in support of cancer vaccines combined with chemotherapy:a pragmatic review of past and present efforts.Iht J Oncol,2006,29:765-777. 被引量:1
  • 7Sakaguchi S,Sakaguchi N,Asano M,et al.Immunologic selftolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25).Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.J Immunol,1995,155:1151-1164. 被引量:1
  • 8NorthRJ.Cyclophosphamide-facilitatedadoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.J Exp Med,1982,155:1063-1074. 被引量:1
  • 9Barrett AJ,Savani BN.Does chemotherapy modify theimmune surveillance of hematological malignancies?.Leukemia,2009,23:53-58. 被引量:1
  • 10Serafini P,Borrello I,Bronte V.Myeloid suppressor cells in cancer:recruitment,phenotype,properties,and mechanisms of immune suppression.Semin Cancer Biol,2006,16:53-65. 被引量:1

二级参考文献25

  • 1罗荣城,尤长宣.肿瘤生物治疗新进展[J].中国新药杂志,2005,14(2):143-146. 被引量:18
  • 2Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target [ J ]. Ann Oncol, 2008, 19 (9) : 1523-1529. 被引量:1
  • 3Rocha-Lima CM, Soares HP, Raez LE, et al. EGFR targeting of solid tumors [ J ]. Cancer Control, 2007, 14 (3) : 295-304. 被引量:1
  • 4Thome S, Hobday T, Hillman D, et al. Translational correlates, including outcome for patients with ER-/PR-/HER2-( triple negative (TNeg)) disease from N0234, a phase Ⅱ trial of gemcitabine and erlotinib for pts with previously treated metastatic breast cancer (MBC) [ EB/OL]. ( 2007 ) [ 2009-04-21 ]. http://meeting, ascopubs, org/ cgi/ content/ abstract/ 25 /18_suppl/1071. 被引量:1
  • 5Munoz A, Salut A, Pericay C, et al. Phase Ⅱ trial of capecit- abine, oxaliplatin plus bevacizumab followed by bevacizumab plus erlotinib : XELOBER trial [ EB/OL ]. ( 2008 ) [ 2009-04-21 ]. http://meeting, ascopubs, org/cgi/content/abstract/26/15 _suppl./ 15078.9 maxtoshow = & HITS = 20 & hits = 20 & RESULTFOR- MAT = & fulhext =c. pericay & searchid = I&FIRSTINDEX =0 & resourcetype = HWCIT. 被引量:1
  • 6Von Minckwitz G, Zielinski C, Maartense E, et al. Capecitabine vs capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment [ EB/OL]. (2008) [ 2009-04-21 ]. http://meeting, ascopubs. org/cgi/content/abstract/26/15 _suppl/1025. 被引量:1
  • 7Cancello G, Montagna E, D'Agostino D, et al. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer [ J]. Breast Cancer Rcs, 2005, 10 (4) : R60. 被引量:1
  • 8Cunningham D, Humbler Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J]. N Engl J Med, 2004, 351 (4): 337- 345. 被引量:1
  • 9Milani M, Harris AL. Targeting tumour hypoxia in breast cancer [J]. Eur J Cancer, 2008, 44( 18): 2766-2773. 被引量:1
  • 10Rho JK, Choi YJ, Lee JK, et al. Gefitinib circumvents hypoxia- induced drug resistance by the modulation of HIF-lalpha[ J]. Oncol Rep, 2009, 21 (3) : 801-807. 被引量:1

共引文献22

同被引文献38

  • 1于丹丹,魏于全.恶性肿瘤的生物化疗研究及进展[J].中华临床医师杂志(电子版),2011,5(16):4828-4830. 被引量:7
  • 2钟华,韩宝惠,董强刚,冯久贤,包国良,沙慧芳,苏建中.肺癌胸腔积液中树突状细胞的诱导培养及功能分析[J].中华结核和呼吸杂志,2004,27(8):542-545. 被引量:7
  • 3黄慧,曾波航,陈静琦,吕嘉春.恶性胸腔积液来源树突状细胞的纯化培养研究[J].肿瘤学杂志,2005,11(2):99-102. 被引量:4
  • 4de Serres G, Rouleau I, Hamelin ME,et al. Contagious piriod for pandemic (H1N1)2009[J]. Emerg Infect Dis,2010,16(5) : 783-788. 被引量:1
  • 5O'Riordan S,Barton M,Yau Y,et al. Risk factors and outcomes among children admitted to hospital with pandemic ttlN1 influenza[J]. CMAJ,2010,182(1 ) :39-44. 被引量:1
  • 6Zarychaski R, Stuart TI., Kumar A. Correlates of severe disease in patients with 2009 pandemic influenza(H1N1) virus infection[J]. CMAJ,2010,182(3) :257-264. 被引量:1
  • 7Quispe-I.aime AM, Braceo JD, Barberio PA, et al. H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment [J]. Intensive Care reed, 2010,36 ( 1 ) : 33-41. 被引量:1
  • 8Castro M, Rubin AS, l.aviolette M, et al. Effectiveness and safety of bronchial tbermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham controlled clinical trial[J]. Am J Respir Crit Care Med,2010, 18(2):116 124. 被引量:1
  • 9Jackson RM, Glassberg MK, Ramos CF, et al. Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis [J], Lung,2010,188 : 115-123. 被引量:1
  • 10Munson JC. Combined pulmonary fibrosis and emphysema: a high pressure situation[J]. Eur Respir J, 2010, 35 (1): 105-111. 被引量:1

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部